Does Comorbidity Influence the Risk of Myocardial Infarction or Diabetes During Androgen-Deprivation Therapy for Prostate Cancer?

被引:64
作者
Keating, Nancy L. [1 ,2 ]
O'Malley, A. James [2 ]
Freedland, Stephen J. [3 ,4 ]
Smith, Matthew R. [5 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA
[3] Durham Vet Affairs Med Ctr, Durham, NC USA
[4] Duke Univ, Dept Surg Urol & Pathol, Duke Prostate Ctr, Durham, NC USA
[5] Massachusetts Gen Hosp MRS, Div Hematol & Oncol, Boston, MA USA
关键词
Prostate cancer; Myocardial infarction; Diabetes; QUALITY-OF-CARE; CARDIOVASCULAR-DISEASE; RADIATION-THERAPY; SUPPRESSION; MEDICARE; MEN; RADIOTHERAPY; NEOADJUVANT; POPULATION; GOSERELIN;
D O I
10.1016/j.eururo.2012.04.035
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Androgen-deprivation therapy (ADT) for prostate cancer (PCa) may be associated with cardiovascular disease and diabetes. Some data suggest that men with certain conditions may be more susceptible to developing cardiovascular disease than others. Objective: To assess whether the risk of myocardial infarction (MI) or diabetes during ADT is modified by specific baseline comorbidities. Design, setting, and participants: We conducted a population-based observational study of 185 106 US men >= 66 yr of age diagnosed with local/regional PCa from 1992 to 2007. We assessed comorbidities monthly over the follow-up period. Outcome measurements and statistical analysis: Cox proportional hazards models with time-varying variables assessing incident diabetes or MI. Results and limitations: A total of 49.9% of the men received ADT during follow-up. Among men with no comorbidities, ADT was associated with an increase in the adjusted hazard of MI (adjusted hazard ratio [AHR]: 1.09; 95% confidence interval [CI], 1.02-1.16) and diabetes (AHR: 1.33; 95% CI, 1.27-1.39). Risks of MI and diabetes were similarly increased among men with and without specific comorbid illnesses (p > 0.10 for all interactions, with one exception). Previous MI, congestive heart failure, peripheral arterial disease, stroke, hypertension, chronic obstructive pulmonary disease, and renal disease were associated with new MI and diabetes, and obesity and rheumatologic disease were also associated with diabetes. Limitations include the observational study design, reliance on administrative data to ascertain outcomes, and lack of information on risk factors such as smoking and family history. Conclusions: Traditional risk factors for MI and diabetes were also associated with developing these conditions during ADT but did not significantly modify the risk attributable to ADT. Strategies to screen and prevent diabetes and cardiovascular disease in men with PCa should be similar to the strategies recommended for the general population. (c) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 29 条
[1]   Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes [J].
Alibhai, Shabbir M. H. ;
Duong-Hua, Minh ;
Sutradhar, Rinku ;
Fleshner, Neil E. ;
Warde, Padraig ;
Cheung, Angela M. ;
Paszat, Lawrence F. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) :3452-3458
[2]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[3]   Duration of Androgen Suppression in the Treatment of Prostate Cancer [J].
Bolla, Michel ;
de Reijke, Theodorus M. ;
Van Tienhoven, Geertjan ;
Van den Bergh, Alphonsus C. M. ;
Oddens, Jorg ;
Poortmans, Philip M. P. ;
Gez, Eliahu ;
Kil, Paul ;
Akdas, Atif ;
Soete, Guy ;
Kariakine, Oleg ;
Van der Steen-Banasik, Elsbietha M. ;
Musat, Elena ;
Pierart, Marianne ;
Mauer, Murielle E. ;
Collette, Laurence .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (24) :2516-2527
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]   National practice patterns and time trends in androgen ablation for localized prostate cancer [J].
Cooperberg, MR ;
Grossfeld, GD ;
Lubeck, DP ;
Carroll, PR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (13) :981-989
[6]   6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial [J].
D'Amico, AV ;
Manola, J ;
Loffredo, M ;
Renshaw, AA ;
DellaCroce, A ;
Kantoff, PW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (07) :821-827
[7]   Prevalence and Trends in Obesity Among US Adults, 1999-2008 [J].
Flegal, Katherine M. ;
Carroll, Margaret D. ;
Ogden, Cynthia L. ;
Curtin, Lester R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (03) :235-241
[8]   Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer [J].
Hall, MC ;
Fritzsch, RJ ;
Sagalowsky, AI ;
Ahrens, A ;
Petty, B ;
Roehrborn, CG .
UROLOGY, 1999, 53 (05) :898-902
[9]   Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke [J].
Hayes, Julia H. ;
Chen, Ming-Hui ;
Moran, Brian J. ;
Braccioforte, Michelle H. ;
Dosoretz, Daniel E. ;
Salenius, Sharon ;
Katin, Michael J. ;
Ross, Rudi ;
Choueiri, Toni K. ;
D'Amico, Anthony V. .
BJU INTERNATIONAL, 2010, 106 (07) :979-985
[10]   Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer [J].
Keating, Nancy L. ;
O'Malley, A. James ;
Smith, Matthew R. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4448-4456